Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Intraperitoneal chemo-hyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis
Autore:
Sayag-Beaujard, AC; Francois, Y; Glehen, O; Sadeghi-Looyeh, B; Bienvenu, J; Panteix, G; Garbit, F; Grandclement, E; Vignal, J; Gilly, FN;
Indirizzi:
Ctr Hosp Univ Lyon Sud, Dept Digest Surg, F-69495 Pierre Benite, France Ctr Hosp Univ Lyon Sud Pierre Benite France F-69495 ierre Benite, France Univ CB Lyon 1, Oncol Hypertherrnia Lab, F-69630 Oullins, France Univ CB Lyon 1 Oullins France F-69630 rrnia Lab, F-69630 Oullins, France CHLS, Dept Intens Care, F-69495 Pierre Benite, France CHLS Pierre BeniteFrance F-69495 ns Care, F-69495 Pierre Benite, France CHLS, Dept Immunol, F-69495 Pierre Benite, France CHLS Pierre Benite France F-69495 Immunol, F-69495 Pierre Benite, France
Titolo Testata:
ANTICANCER RESEARCH
fascicolo: 2B, volume: 19, anno: 1999,
pagine: 1375 - 1382
SICI:
0250-7005(199903/04)19:2B<1375:ICWMCF>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
CYTOREDUCTIVE SURGERY; CHEMOTHERAPY; CHEMOHYPERTHERMIA; CELLS; THERMOCHEMOTHERAPY; MORTALITY; PERFUSION; SURVIVAL;
Keywords:
peritoneal carcinomatosis; gastric cancer; hyperthermia; mitomycin C;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
29
Recensione:
Indirizzi per estratti:
Indirizzo: Gilly, FN CHLS, Dept Digest Surg, F-69495 Pierre Benite, France CHLS Pierre Benite France F-69495 -69495 Pierre Benite, France
Citazione:
A.C. Sayag-Beaujard et al., "Intraperitoneal chemo-hyperthermia with mitomycin C for gastric cancer patients with peritoneal carcinomatosis", ANTICANC R, 19(2B), 1999, pp. 1375-1382

Abstract

Objective: This study evaluates the tolerance and efficacy of Intraperitoneal Chemohyperthermia (IPCH) with Mitomycin C (MMC) associated with surgery, in peritoneal carcinomatosis of gastric origin. Background: Most patientswith peritoneal carcinomatosis of gastric origin die within 6 months, and IPCH associated with surgery has been reported as a possible new therapeutic approach. Methods: A prospective non randomized trial was carried out on 42 patients with gastric cancers and peritoneal carcinomatosis. Fourty three IPCH with MMC were used as complementary treatment after surgery (peritoneal perfusate with a 10 mg/l dose of MMC, inflow temperature 46 to 49 degrees C, use of a closed circuit, duration 90 minutes). Fourteen primary tumors were unresectable ones and 12 patients had large malignant preoperative ascites. Results: Mortality and morbidity rates were 2/42 and 4/42 respectively. For resectable gastric cancers with :stage I and 2 carcinomatosis (malignant granulations less than 5 mm in diameter), one, two and three year survival rates were 80, 61 and 41% respectively. For unresectable primary tumors and for stage 3 and 4 carcinomatosis (granulations larger than 5 mm in diameter), six and twelve month survival rates were 50% and 10% respectively. Conclusions: IPCH appears as a safe new therapeutic approach in gastric cancers with peritoneal carcinomatosis with small malignant granulations (stage I and 2) and randomized trials are now needed to clearly evaluate its efficacy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/12/20 alle ore 07:36:46